Abstract:The inflammatory cell model of human mononuclear macrophage (THP‐1) cells induced by lipopolysaccharide (LPS) was established to study the effect of Dexmedetomidine (DEX) on the expression of cell‐related inflammatory factors. ADRA2A gene knockout THP‐1 cells (THP‐1KO) were constructed, and the effect of DEX on the expression of inflammatory factors of THP‐1KO cells was detected. The target sites of DEX on β2 AR were screened by molecular docking. Reversion experiments were performed using ADRB2siRNA. The results showed that DEX significantly decreased the expression of MCP‐1, interleukin‐06, and IL‐8 in THP‐1 and THP‐1KO cells induced by the LPS, and increased the level of IL‐10. Immunofluorescence results showed that β2 adrenergic receptor (β2 AR) expression increased after DEX treatment. DEX significantly increased the activation of β2 AR and PKA/CREB pathways, inhibited the activation of NF‐κB. ADRB2 siRNA reversed the effects of DEX and promoted the release of inflammatory cytokines Introduction Dexmedetomidine (DEX) is primarily utilized for sedation in the context of general anesthesia or intensive care. However, the exact regulatory mechanism by which DEX affects cytokines remains unclear. This study aims to investigate the underlying mechanism by which DEX inhibits proinflammatory factors through activation of the β2 adrenergic receptor (β2 AR). Methods The inflammatory cell model of human mononuclear macrophage (THP‐1) cells induced by lipopolysaccharide (LPS) was established to study the effect of DEX on the expression of cell‐related inflammatory factors. ADRA2A gene knockout THP‐1 cells (THP‐1KO) were constructed by CRISPR technology, and the effect of DEX on the expression of inflammatory factors of THP‐1KO cells was detected. The target sites of DEX on β2 AR were screened by molecular docking. Reversion experiments were performed using ADRB2‐siRNA. Western blot was used to detect the activation of β2 AR/PKA/CREB pathway and NF‐κB, and ELISA was used to detect the release level of inflammatory factors. Results The results demonstrated a significant reduction in the expression levels of MCP‐1, interleukin‐06, and IL‐8 in both THP‐1 and THP‐1KO cells when induced by LPS following treatment with DEX. Additionally, DEX treatment led to an increase in IL‐10 expression. Immunofluorescence analysis revealed an upregulation of β2 AR expression after DEX treatment. Western blot results indicated that DEX notably enhanced the activation of the β2 AR and PKA/CREB pathways, while concurrently suppressing the activation of NF‐κB. Notably, the use of ADRB2 siRNA reversed the effects of DEX treatment and promoted the release of inflammatory cytokines. Conclusion DEX initiates the activation of the PKA/CREB pathway through the activation of β2 AR. Simultaneously, it exerts an inhibitory effect on the activation of NF‐κB, consequently reducing the transcription of proinflammatory factors while increasing the transcription of anti‐inflammatory factors.

Dexamethasone induced inhibition of Dectin-1 activation of antigen presenting cells is mediated via STAT-3 and NF-κB signaling pathways

Dexamethasone inhibits the antigen presentation of dendritic cells in MHC class II pathway.

Glucocorticoids Affect Human Dendritic Cell Differentiation and Maturation

Dexamethasone Enhances Programmed Cell Death 1 (PD-1) Expression During T Cell Activation: an Insight into the Optimum Application of Glucocorticoids in Anti-Cancer Therapy

Inhibition of Nerve Growth Factor-Induced Neurite Outgrowth from PC12 Cells by Dexamethasone: Signaling Pathways through the Glucocorticoid Receptor and Phosphorylated Akt and ERK1/2

Glucocorticoids control allergic inflammation via Foxp3+regulatory T cells

Revisit the Inhibitory Effects of Glucocorticoids on Immunocytes

The glucocorticoid dexamethasone alleviates allergic inflammation through a mitogen‐activated protein kinase phosphatase‐1‐dependent mechanism in mice

Inhibition of IFN-gamma Signaling by Glucocorticoids.

Activation of the mitogen-activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells

Glucocorticoid receptor agonist compound K regulates Dectin-1-dependent inflammatory signaling through inhibition of reactive oxygen species

Dexmedetomidine activates the PKA/CREB pathway and inhibits proinflammatory factor expression through β2 adrenergic receptors

Dexamethasone suppresses osteogenesis of osteoblast via the PI3K/Akt signaling pathway in vitro and in vivo

An in Vitro and in Vivo Study of the Effect of Dexamethasone on Immunoinhibitory Function of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells.

NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment

Dexamethasone Selectively Retains Tolerogenic Macrophages in the Spleen

Activation of NF-κB and Respiratory Burst Following Aspergillus Fumigatus Stimulation of Macrophages

Dectin-1 Signaling Update: New Perspectives for Trained Immunity

Glucan from <i>Dictyophora rubrovolvata</i> boosts immunity by regulating AKT-STAT1 pathway to induce dendritic cells maturation and T cells differentiation

Dexamethasone Promotes Tolerance in Vivo by Enriching CD11clo CD40lo Tolerogenic Macrophages.

Role and mechanism of the Dectin-1-mediated Syk/NF-κB signaling pathway in Talaromyces marneffei infection